PulseAugur
EN
LIVE 21:15:34
中文(ZH) 华东医药：子公司医疗器械变更注册申请获受理

Huadong Medicine subsidiary's facial filler application accepted for new indication

By PulseAugur Editorial · [1 sources] ·

Huadong Medicine's subsidiary, Xinkelimayxue, has received acceptance for a change registration application for its medical device, Ellansé® S-type. This application seeks to expand the approved uses of the injectable poly-L-lactic acid facial filler to include implantation in the subcutaneous or periosteal layers of the forehead for correcting moderate to severe forehead contour defects. The company also announced the establishment of Zhejiang Wuju Neng Supply Chain Management Co., Ltd., with a registered capital of 100 million RMB, focusing on supply chain management and sales. AI

RANK_REASON This is a product update for a medical device, not a core AI development.

Read on 36氪 (36Kr) →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

Huadong Medicine subsidiary's facial filler application accepted for new indication

How we ranked this

Signal score
0 / 100
Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket
Tool
This is a product update for a medical device, not a core AI development.
Source corroboration
Single-source cluster
Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
Topics
product, other
Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance
Low
Off-topic or adjacent — cluster remains reachable but doesn't surface in AI-industry rankings.
Story freshness
109 days old
Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

Full methodology in our editorial standards.

COVERAGE [1]

  1. 36氪 (36Kr) TIER_1 中文(ZH) ·

    Huadong Medicine: Subsidiary's Medical Device Change Registration Application Accepted

    36氪获悉，华东医药公告，6月8日，公司全资子公司欣可丽美学（杭州）供应链管理有限公司收到国家药品监督管理局签发的《受理通知书》，其代理申报的三类医疗器械注射用聚己内酯微球面部填充剂Ellansé®伊妍仕®S型拓展新适用症的变更注册申请获得受理，本次申请新增适用症：用于额部皮下或骨膜上植入，以改善中至重度额部轮廓缺陷。

RELATED TOPICS